Type I lamellar ichthyosis improved by tazarotene 0.1% gel

G. C. Marulli, E. Campione, M. S. Chimenti, A. Terrinoni, G. Melino, L. Bianchi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The efficacy of tazarotene 0.1% gel in a 30-year-old woman with type I lamellar ichthyosis is reported. The drug was applied to 15% of the total body surface area as follows: once daily for 2 weeks, three times a week for further 2 weeks, followed by a once weekly maintenance application. During the first week of treatment there was partial improvement obtained and in the next 14 days further reduction of scaling within the tazarotene-treated areas was observed. After 4 months of maintenance application, there was a marked overall improvement in the treated areas. Side-effects consisted only of mild pruritus, slight burning and irritation. In essence, the therapeutic benefit obtained was comparable with that of systemic retinoids but without the adverse systemic side-effects. As noted in other reports, tazarotene 0.1% gel seems to be a valuable and safe therapeutic option for this severe genodermatosis.

Original languageEnglish
Pages (from-to)391-393
Number of pages3
JournalClinical and Experimental Dermatology
Volume28
Issue number4
DOIs
Publication statusPublished - Jun 2003

Fingerprint

Lamellar Ichthyosis
Gels
Maintenance
Body Surface Area
Retinoids
Pruritus
Therapeutics
Pharmaceutical Preparations
tazarotene

ASJC Scopus subject areas

  • Dermatology

Cite this

Marulli, G. C., Campione, E., Chimenti, M. S., Terrinoni, A., Melino, G., & Bianchi, L. (2003). Type I lamellar ichthyosis improved by tazarotene 0.1% gel. Clinical and Experimental Dermatology, 28(4), 391-393. https://doi.org/10.1046/j.1365-2230.2003.01318.x

Type I lamellar ichthyosis improved by tazarotene 0.1% gel. / Marulli, G. C.; Campione, E.; Chimenti, M. S.; Terrinoni, A.; Melino, G.; Bianchi, L.

In: Clinical and Experimental Dermatology, Vol. 28, No. 4, 06.2003, p. 391-393.

Research output: Contribution to journalArticle

Marulli, GC, Campione, E, Chimenti, MS, Terrinoni, A, Melino, G & Bianchi, L 2003, 'Type I lamellar ichthyosis improved by tazarotene 0.1% gel', Clinical and Experimental Dermatology, vol. 28, no. 4, pp. 391-393. https://doi.org/10.1046/j.1365-2230.2003.01318.x
Marulli, G. C. ; Campione, E. ; Chimenti, M. S. ; Terrinoni, A. ; Melino, G. ; Bianchi, L. / Type I lamellar ichthyosis improved by tazarotene 0.1% gel. In: Clinical and Experimental Dermatology. 2003 ; Vol. 28, No. 4. pp. 391-393.
@article{c7369f91f15a474f8454de5891d00e34,
title = "Type I lamellar ichthyosis improved by tazarotene 0.1{\%} gel",
abstract = "The efficacy of tazarotene 0.1{\%} gel in a 30-year-old woman with type I lamellar ichthyosis is reported. The drug was applied to 15{\%} of the total body surface area as follows: once daily for 2 weeks, three times a week for further 2 weeks, followed by a once weekly maintenance application. During the first week of treatment there was partial improvement obtained and in the next 14 days further reduction of scaling within the tazarotene-treated areas was observed. After 4 months of maintenance application, there was a marked overall improvement in the treated areas. Side-effects consisted only of mild pruritus, slight burning and irritation. In essence, the therapeutic benefit obtained was comparable with that of systemic retinoids but without the adverse systemic side-effects. As noted in other reports, tazarotene 0.1{\%} gel seems to be a valuable and safe therapeutic option for this severe genodermatosis.",
author = "Marulli, {G. C.} and E. Campione and Chimenti, {M. S.} and A. Terrinoni and G. Melino and L. Bianchi",
year = "2003",
month = "6",
doi = "10.1046/j.1365-2230.2003.01318.x",
language = "English",
volume = "28",
pages = "391--393",
journal = "Clinical and Experimental Dermatology",
issn = "0307-6938",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Type I lamellar ichthyosis improved by tazarotene 0.1% gel

AU - Marulli, G. C.

AU - Campione, E.

AU - Chimenti, M. S.

AU - Terrinoni, A.

AU - Melino, G.

AU - Bianchi, L.

PY - 2003/6

Y1 - 2003/6

N2 - The efficacy of tazarotene 0.1% gel in a 30-year-old woman with type I lamellar ichthyosis is reported. The drug was applied to 15% of the total body surface area as follows: once daily for 2 weeks, three times a week for further 2 weeks, followed by a once weekly maintenance application. During the first week of treatment there was partial improvement obtained and in the next 14 days further reduction of scaling within the tazarotene-treated areas was observed. After 4 months of maintenance application, there was a marked overall improvement in the treated areas. Side-effects consisted only of mild pruritus, slight burning and irritation. In essence, the therapeutic benefit obtained was comparable with that of systemic retinoids but without the adverse systemic side-effects. As noted in other reports, tazarotene 0.1% gel seems to be a valuable and safe therapeutic option for this severe genodermatosis.

AB - The efficacy of tazarotene 0.1% gel in a 30-year-old woman with type I lamellar ichthyosis is reported. The drug was applied to 15% of the total body surface area as follows: once daily for 2 weeks, three times a week for further 2 weeks, followed by a once weekly maintenance application. During the first week of treatment there was partial improvement obtained and in the next 14 days further reduction of scaling within the tazarotene-treated areas was observed. After 4 months of maintenance application, there was a marked overall improvement in the treated areas. Side-effects consisted only of mild pruritus, slight burning and irritation. In essence, the therapeutic benefit obtained was comparable with that of systemic retinoids but without the adverse systemic side-effects. As noted in other reports, tazarotene 0.1% gel seems to be a valuable and safe therapeutic option for this severe genodermatosis.

UR - http://www.scopus.com/inward/record.url?scp=0038045493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038045493&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2230.2003.01318.x

DO - 10.1046/j.1365-2230.2003.01318.x

M3 - Article

C2 - 12823301

AN - SCOPUS:0038045493

VL - 28

SP - 391

EP - 393

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

SN - 0307-6938

IS - 4

ER -